Veracyte, Inc.
VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$41.70
Price+0.02%
$0.01
1Y
Price
Market Cap
$3.296b
Mid
Price/Earnings 3y Avg5y Avg
109.7x
Premium
Premium
Financials Overview
Key metrics over the past few years+15.2%
EBITDA Margin-0.7%
Net Profit Margin+2.7%
Free Cash Flow MarginRevenue
$479.129m
+7.5%
1y CAGR+17.6%
3y CAGR+22.0%
5y CAGREarnings
$26.335m
+9.1%
1y CAGR+12.7%
3y CAGR+22.4%
5y CAGREPS
$0.33
+6.5%
1y CAGR+12.3%
3y CAGR+22.7%
5y CAGRBook Value
$1.221b
$1.344b
Assets$123.047m
Liabilities$50.646m
DebtDebt to Assets
3.8%
0.9x
Debt to EBITDAFree Cash Flow
$55.190m
-13.5%
1y CAGR+1183.8%
3y CAGR+912.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company